Saturday, October 25, 2014

Stellar in KLH supply pact with Biovest

Stellar in KLH supply pact with Biovest

October 23, 2014 by · Leave a Comment 

Tweet Stellar Biotechnologies (OTCQB:SBOTF; TSX-V:KLH) and Biovest International have executed a definitive supply agreement to meet Biovest’s requirements for Keyhole Limpet Hemocyanin (KLH) for use in its BiovaxID active immunotherapy to treat follicular non-Hodgkin’s lymphoma. BiovaxID combines autologous heterohybridoma-derived tumor idiotype protein coupled to KLH as the carrier molecule. BiovaxID has successfully completed Phase 2 […]

HCW starts Advaxis at buy

HCW starts Advaxis at buy

October 23, 2014 by · Leave a Comment 

Tweet H.C. Wainwright has initiated coverage of Advaxis (NASDAQ:ADXS) with a “buy” rating and $8 price target. The stock closed at $2.84 on Wednesday. Advaxis’ strategy is to monetize a novel platform and to enter into partnerships to become a major player in the cancer immunotherapy market, writes analyst Swayampakula Ramakanth. The company’s platform utilizes […]

Nuvo sees $1-billion in peak yearly WF10 sales

Nuvo sees $1-billion in peak yearly WF10 sales

October 22, 2014 by · Leave a Comment 

Tweet Nuvo Research (TSX:NRI) has released the results of a market study that forecasts its WF10 treatment could capture 10% to 15% of the U.S. refractory allergic rhinitis market with peak U.S. annual sales of $700-million to $1.1-billion. The study was preformed by Psscion Lifesciences Consulting to investigate the U.S. opportunity for WF10, an experimental […]

Novadaq inks Japan distribution deal with Mizuho Medical

Novadaq inks Japan distribution deal with Mizuho Medical

October 21, 2014 by · Leave a Comment 

Tweet Novadaq Technologies (NASDAQ:NVDQ; TSX:NDQ) has entered into an exclusive five-year agreement with Mizuho Medical for the distribution of its PINPOINT Endoscopic Fluorescence Imaging System in Japan. “The agreement with Mizuho Medical further strengthens our ability to achieve growth through our commitment to globalization,” Dr. Arun Menawat, president and CEO of Novadaq, said in a […]

Rosetta Genomics in pact for thyroid cancer diagnostic

Rosetta Genomics in pact for thyroid cancer diagnostic

October 21, 2014 by · Leave a Comment 

Tweet Rosetta Genomics (NASDAQ:ROSG) has initiated a new public-private translational research project with the Institute of Molecular Translational Medicine (IMTM) at Palacky University, Olomouc, Czech Republic. The new partnership will work towards the validation and development of a new thyroid cancer diagnostic tool. The partnership was facilitated by the European Infrastructure for Translational Medicine (EATRIS) […]

HCW starts Oncothyreon at buy

HCW starts Oncothyreon at buy

October 21, 2014 by · Leave a Comment 

Tweet H.C. Wainwright has launched coverage of Oncothyreon (NASADQ:ONTY) with a “buy” rating and 12-month target price of $4, based on a risk-adjusted revenue and EPS multiples valuation methodology. The stock finished at $1.73 on Monday. “Oncothyreon’s biotechnology franchise is comprised of diverse set of therapeutics, including ONT-380, a potent and highly specific tyrosine kinase […]

Stifel starts Vitae Pharma at buy

Stifel starts Vitae Pharma at buy

October 20, 2014 by · Leave a Comment 

Tweet Stifel has initiated coverage of Vitae Pharmaceuticals (NASDAQ:VTAE) with a “buy” rating and price target of $14. The stock closed at $6.30 on Friday. “Vitae’s unique technology platform encompasses the unique ability to rationally design clinical candidates and represents the principal competitive advantage of the company,” writes analyst Dr. Brian Klein. He said Vitae’s CONTOUR […]

Nuvo Research sells U.S. Pennsaid 2% rights to Horizon


Nuvo Research sells U.S. Pennsaid 2% rights to Horizon


October 17, 2014 by · Leave a Comment 

Tweet Nuvo Research (TSX:NRI) has sold the U.S. sales and marketing rights of its Pennsaid 2% topical pain reliever to Horizon Pharma (NASDAQ:HZNP) for a cash payment of $45-million. Effective Jan. 1, 2015, Horizon will assume U.S. commercialization of Pennsaid 2% from Nuvo’s former U.S. marketing licensee. Nuvo retains all rights to Pennsaid and Pennsaid […]

Novadaq signs India distribution deal with Kirloskar

Novadaq signs India distribution deal with Kirloskar

October 16, 2014 by · Leave a Comment 

Tweet Novadaq Technologies (NASDAQ:NVDQ; TSX:NDQ) has appointed Kirloskar Technologies as the exclusive distributor for its family of fluorescence imaging technologies in India. The relationship between the two companies officially kicked off today with a signing ceremony overseen by the Honourable Ed Fast, Canada’s Minister of International Trade, at the Taj Palace Hotel in New Delhi “NOVADAQ’s products […]

Roth adds MEI Pharma to Focus List, ups price target to $22

Roth adds MEI Pharma to Focus List, ups price target to $22

October 16, 2014 by · Leave a Comment 

Tweet Roth Capital Partners has added “buy-rated” MEI Pharma (NASDAQ:MEIP) to its Focus List and raised its price target to $22 from $20. The stock closed at $7.68 on Wednesday. Analyst Joseph Pantginis writes that MEI is well positioned with its lead oral HDAC inhibitor, pracinostat, for the treatment of acute myeloid leukemia (AML) and […]

Next Page »

Email Newsletters with Constant Contact
Google+